Aripiprazole in pediatric psychosis and bipolar disorder: A clinical review

Doey, Tamison

doi:10.1016/j.jad.2012.02.031

Cited by 14 publications

(11 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study begins to provide some answers to this question with unanticipated results. The similarity in BMI Z-score change with both treatment groups is unexpected, given data from other disorders suggesting that less weight gain is associated with aripiprazole use than with other atypical antipsychotics in both youth and adults (Correll et al 2009;Stroup et al 2011;Ben Amor 2012;Cohen et al 2012;Doey 2012). Weight gain is a primary adverse effect of concern with atypical antipsychotics in ASD.…”

Section: Discussionmentioning

confidence: 95%

Body Mass Index Change in Autism Spectrum Disorders: Comparison of Treatment with Risperidone and Aripiprazole

Wink

Early

Schaefer

et al. 2014

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objective: The purpose of this study was to assess change in body mass index (BMI) and age-and gender-adjusted BMI Z-score in subjects ages 2-20 years with autism spectrum disorders (ASD), who were treated longitudinally with risperidone or aripiprazole at a tertiary care ASD clinic. Method: As part of a larger project involving longitudinal drug treatment data in ASD, detailed demographic and treatment data were collected for 142 subjects ages 2-20 years who had been started on risperidone or aripiprazole for treatment of irritability. Mean age at start of treatment, treatment duration, final Clinical Global Impressions-Improvement Scale score, BMI change per year of treatment, and BMI Z-score change per year of treatment (primary outcome measure) were calculated for each drug treatment group. Group means were compared using t tests and Wilcoxon rank sum tests. Results: There was a statistically significant BMI and BMI Z-score increase in the risperidone and aripiprazole treatment groups individually. No statistically significant difference between the two treatment groups was noted in mean BMI change per year of treatment or BMI Z-score change per year of treatment. Conclusions: In our review of long-term naturalistic treatment of irritability using risperidone versus aripiprazole in persons with ASD, a significant increase in both BMI and age-and gender-adjusted BMI Z-score was noted for each treatment group. No significant difference in BMI or BMI Z-score change was noted when the two treatment groups were compared. We conclude that in our patient population at a tertiary care ASD clinic, the effects of risperidone and aripiprazole on body weight gain in naturalistic long-term treatment are no different.

show abstract

Section: Discussionmentioning

confidence: 95%

Body Mass Index Change in Autism Spectrum Disorders: Comparison of Treatment with Risperidone and Aripiprazole

Wink

Early

Schaefer

et al. 2014

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Aripiprazole may be the preferred option in younger children, considering that it is the only strategy that has been specifically assessed in this age group, for which it has been shown to be efficacious. There is also its relatively benign adverse event profile, with lower metabolic risk and lower risk of prolactin elevation (Findling et al., , ), as compared with other SGAs (Doey, ). The main concerns related to aripiprazole would be the development of extrapyramidal symptoms and akathisia, which seem to be dose‐dependent (Findling et al., ).…”

Section: Discussionmentioning

confidence: 99%

Practitioner Review: Long‐term pharmacological treatment of pediatric bipolar disorder

Díaz‐Caneja

Moreno

Llorente

et al. 2014

Child Psychology Psychiatry

View full text Add to dashboard Cite

show abstract

“…The emergence of atypical antipsychotics has provided treatments with fewer neurological side effects and greater tolerability. 18 Furthermore, it is suggested that typical antipsychotic therapy in the pediatric population can induce or worsen depression, 19 while atypical antipsychotics may prevent or delay depression development among patients with bipolar disorder. 20 – 22…”

Section: Introductionmentioning

confidence: 99%

“…25 Randomized clinical trials (RCTs) demonstrated that risperidone, 26 quetiapine, 27 and olanzapine 28 were significantly superior to placebo; however, increased experience with these drugs revealed drawbacks to these newer medications, including weight gain and other metabolic and endocrine side effects. 18 The introduction of aripiprazole in the mid-1990s provided another option for child and adolescent psychiatrists as well as for generalists. 29 …”

Section: Introductionmentioning

confidence: 99%

Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents

Kirino

2014

AHMT

View full text Add to dashboard Cite

Bipolar disorder is a pernicious illness. Compared with the later-onset form, early onset bipolar disorder is associated with worse psychosocial outcomes, and is characterized by rapid cycling and increased risks of substance abuse and suicide attempts. Controlling mood episodes and preventing relapse in this group of pediatric patients requires careful treatment. Here, we review the effectiveness of aripiprazole for bipolar disorder in children and adolescents, with discussion of this drug’s unique pharmacological profile and various clinical study outcomes. Aripiprazole acts as a serotonin 5-HT2A receptor antagonist, as well as a partial agonist of the serotonin 5-HT1A and dopamine D2 receptors. It can be safely used in children and adolescents, as it is highly tolerated and shows lower rates of the side effects typically observed with other antipsychotic drugs, including sedation, weight gain, hyperprolactinemia, and extrapyramidal syndrome. The presently reviewed randomized controlled trials (RCTs) and non-RCTs generally reported aripiprazole to be effective and well-tolerated in children and adolescents with bipolar disorder. However, due to the limited number of RCTs, the present conclusions must be evaluated cautiously. Furthermore, aripiprazole cannot yet be considered a preferred treatment for children and adolescents with bipolar disorder, as there is not yet evidence that aripiprazole shows greater efficacy compared to other second-generation antipsychotics. Additional data are needed from future head-to-head comparison studies.

show abstract

Aripiprazole in pediatric psychosis and bipolar disorder: A clinical review

Cited by 14 publications

References 50 publications

Body Mass Index Change in Autism Spectrum Disorders: Comparison of Treatment with Risperidone and Aripiprazole

Body Mass Index Change in Autism Spectrum Disorders: Comparison of Treatment with Risperidone and Aripiprazole

Practitioner Review: Long‐term pharmacological treatment of pediatric bipolar disorder

Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents

Contact Info

Product

Resources

About